MBIO (Mustang Bio Inc.) stock: $0.40, $3.0M market cap, $14.3M cash, -$11.3M EV, $4.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
Mustang Bio, Inc. (“Mustang,” “we,” “us,” “our” or the “Company”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs into potential cures for difficult-to-treat cancers. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note FDA safe-to-proceed letter October 2023 for Phase 1 IND; investigator-sponsored trial under COH IND potentially initiating Q4 2026.
CD20 CAR-T
Stage not disclosed · TerminatedModality: CAR T cell therapy
Target CD20
Partnerships Fred Hutch (CD20 License terminated December 2025)
Indications
not disclosed(Stage not disclosed)
Status note CD20 License with Fred Hutch terminated December 2025; Mustang eligible for royalties on subsequent Fred Hutch licensing consideration for three years.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia; Early Relapse of Acute Myeloid Leukemia
—
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.